A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form.

Equipe de Recherche Technologique, Conception, Ingénierie et Développement de l'Aliment et du Médicament (ERT CIDAM), groupe biopharmaceutique, Faculté de pharmacie, 28 place Henri Dunant, 63000 Clermont-Ferrand, France.
European Journal of Pharmaceutical Sciences (Impact Factor: 3.01). 02/2006; 27(1):72-9. DOI: 10.1016/j.ejps.2005.08.006
Source: PubMed

ABSTRACT The first purpose of this study was to simulate the impact of food intake on drug release and absorption in vivo using a novel in vitro system which mimics the gastro-intestinal (GI) tract in man. The drug studied was acetaminophen in the form of immediate release (IR) tablets. The second purpose was to establish a level A in vitro/in vivo correlation that could predict the bioavailability of a drug instead of using difficult, time-consuming and expensive in vivo bioequivalence studies. The artificial digestive system was used to estimate the availability of acetaminophen IR tablets for absorption in fasted and fed states. The same study was performed in vivo under similar conditions. A comparison study was carried out between the classical and the novel methods to estimate the efficacy of the new in vitro system to simulate the influence of food on drug release and absorption in vivo. A level A in vitro/in vivo correlation was established with a correlation coefficient of 0.9128 and 0.9984 in the fasted and fed states, respectively. Compared to USP II method, the novel in vitro model demonstrated a high level of efficacy in mimicking the behaviour of acetaminophen IR tablets in vivo in fasted and fed states.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Methods to understand and predict the oral bioavailability of drug products are a prioritized research area within the pharmaceutical industry. Models to predict oral bioavailability have the potential to reduce risk, time, and cost in development as well as decrease the need for animal studies. The TNO intestinal model (TIM-1) is an advanced dissolution model deployed by AstraZeneca since 2008. This article presents a systematic evaluation of TIM-1 against in vivo data. The relative performance of compounds and formulations tested in TIM-1 and in vivo was compared both by a qualitative analysis and a linear regression analysis of relative exposure measures between test and reference formulations in TIM-1 and in vivo. The TIM-1 correctly predicted in vivo rank order in 84% and 79% of cases for AUC and Cmax , respectively, when using the 3-h time point. There was only one case for Cmax in which TIM-1 did not predict an in vivo difference. The correlation coefficient (R(2) ) between relative (test vs. reference formulations) fraction available in TIM-1 after 3 h and AUC was 0.78. Thus, this study suggests that the TIM-1 system can be used to assess the risk for significant differences in exposure between formulations and compound modifications. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
    Journal of Pharmaceutical Sciences 11/2014; 103(11). DOI:10.1002/jps.24177 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Capsaicin, as a food additive, has attracted worldwide concern owing to its pungency and multiple pharmacologic effects. However, poor water solubility and low bioavailability limited its application. This study aims to develop capsaicin-loaded microemulsion to enhance the oral bioavailability of the anti-neuropathic-pain component, capsaicin, which is poorly water soluble.ResultsIn this study, the microemulsion consisting of Cremophor EL, ethanol, medium chain triglycerides (oil phase) and water (external phase) was prepared and characterized (particle size, morphology, stability and encapsulation efficiency). The gastric mucosa irritation test of formulated capsaicin was performed in rats to evaluate its oral feasibility, followed by the pharmacokinetic study in vivo. Under these conditions, the encapsulated capsaicin revealed a faster capsaicin release in vitro coupled with a greater absorption in vivo when compared to the free capsaicin. The oral bioavailability of the formulated capsaicin-loaded microemulsions was 2.64-fold faster than that of free capsaicin. No significant irritation was observed on the mucosa from the pathological section of capsaicin-loaded microemulsion treated stomach.Conclusion These results indicate that the developed microemulsion represents a safe and orally effective carrier for poorly soluble substance. And the formulation could be used for clinical trials and expand the application of capsaicin.
    Journal of the Science of Food and Agriculture 11/2014; DOI:10.1002/jsfa.7002 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The principal aim of this study was to develop, validate, and demonstrate a physiologically based pharmacokinetic (PBPK) model to predict and characterize the absorption, distribution, metabolism, and excretion of acetaminophen (APAP) in humans. A PBPK model was created that included pharmacologically and toxicologically relevant tissue compartments and incorporated mechanistic descriptions of the absorption and metabolism of APAP, such as gastric emptying time, cofactor kinetics, and transporter-mediated movement of conjugated metabolites in the liver. Through the use of a hierarchical Bayesian framework, unknown model parameters were estimated using a large training set of data from human pharmacokinetic studies, resulting in parameter distributions that account for data uncertainty and inter-study variability. Predictions from the model showed good agreement to a diverse test set of data across several measures, including plasma concentrations over time, renal clearance, APAP absorption, and pharmacokinetic and exposure metrics. The utility of the model was then demonstrated through predictions of cofactor depletion, dose response of several pharmacokinetic endpoints, and the relationship between APAP biomarker levels in the plasma and those in the liver. The model addressed several limitations in previous PBPK models for APAP, and it is anticipated that it will be useful in predicting the pharmacokinetics of APAP in a number of contexts, such as extrapolating across doses, estimating internal concentrations, quantifying population variability, assessing possible impacts of drug coadministration, and, when coupled with a suitable pharmacodynamic model, predicting toxicity.
    European Journal of Drug Metabolism and Pharmacokinetics 01/2015; DOI:10.1007/s13318-015-0253-x · 1.31 Impact Factor


Available from
Oct 31, 2014